{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:37:36Z","timestamp":1792784256971,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,27]],"date-time":"2016-03-27T00:00:00Z","timestamp":1459036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31502050"],"award-info":[{"award-number":["31502050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heilongjiang Funds for Young Scientists","award":["QC2012C099"],"award-info":[{"award-number":["QC2012C099"]}]},{"name":"Department for Heilongjiang education fund","award":["12541046"],"award-info":[{"award-number":["12541046"]}]},{"name":"Department for Harbin science and technology Funds for Young Scientists","award":["2014RFQXJ118"],"award-info":[{"award-number":["2014RFQXJ118"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jphs.2016.03.012","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T20:15:11Z","timestamp":1461960911000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Recombinant Newcastle disease virus (NDV\/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy"],"prefix":"10.1016","volume":"132","author":[{"given":"Yunzhou","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiechao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2016.03.012_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"Vaha-Koskela","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jphs.2016.03.012_bib2","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/mt.2008.181","article-title":"Recombinant Newcastle disease virus as a vaccine vector for cancer therapy","volume":"16","author":"Vigil","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.jphs.2016.03.012_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virusres.2008.04.020","article-title":"Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy","volume":"136","author":"Zhao","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib6","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib7","first-page":"507","article-title":"Newcastle disease virus as an oncolytic agent","volume":"130","author":"Ravindra","year":"2009","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib8","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1128\/JVI.02618-05","article-title":"Differentially regulated interferon response determines the outcome of Newcastle disease virus infection","volume":"80","author":"Krishnamurthy","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jphs.2016.03.012_bib10","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/viro.2002.1413","article-title":"Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus","volume":"297","author":"Zeng","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.jphs.2016.03.012_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01741084","article-title":"Interleukin-2 in cancer treatment: disappointing or (still) promising? A review","volume":"36","author":"Maas","year":"1993","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jphs.2016.03.012_bib13","series-title":"Interleukin-2 and interleukin-2 receptor","author":"Gaffen","year":"1998"},{"key":"10.1016\/j.jphs.2016.03.012_bib14","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1128\/JVI.74.15.7151-7157.2000","article-title":"Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines","volume":"74","author":"Bukreyev","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virusres.2007.07.008","article-title":"Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone","volume":"129","author":"Estevez","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib16","article-title":"Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism","author":"Zhang","year":"2015","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7785\/tcrt.2012.500356","article-title":"Recombinant Newcastle disease virus Anhinga strain (NDV\/Anh-EGFP) for hepatoma therapy","volume":"13","author":"Wu","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jphs.2016.03.012_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00316069","article-title":"Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O","volume":"97","author":"Ramirez-Zacarias","year":"1992","journal-title":"Histochemistry"},{"key":"10.1016\/j.jphs.2016.03.012_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jphs.2015.08.009","article-title":"EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model","volume":"129","author":"Yang","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2016.03.012_bib20","article-title":"Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induced cell apoptosis by targeting ERBB2","author":"Wang","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2016.03.012_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jphs.2015.11.001","article-title":"Resveratrol, a potential radiation sensitizer for glioma stem cells both in\u00a0vitro and in\u00a0vivo","volume":"129","author":"Wang","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2016.03.012_bib22","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/jnci\/91.20.1708","article-title":"Scientific interest in Newcastle disease virus is reviving","volume":"91","author":"Nelson","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jphs.2016.03.012_bib23","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jphs.2016.03.012_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03401771","article-title":"A\u00a015-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire","volume":"4","author":"Batliwalla","year":"1998","journal-title":"Mol Med"},{"key":"10.1016\/j.jphs.2016.03.012_bib25","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2016.03.012_bib27","first-page":"21","article-title":"Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma","volume":"2","author":"Ockert","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jphs.2016.03.012_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.gt.3300787","article-title":"Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus","volume":"6","author":"Schirrmacher","year":"1999","journal-title":"Gene Ther"},{"key":"10.1016\/j.jphs.2016.03.012_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A\u00a0ten-year follow-up on stage \u2161 malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/j.jphs.2016.03.012_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/cbr.1994.9.225","article-title":"Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus","volume":"9","author":"Zorn","year":"1994","journal-title":"Cancer Biother"},{"key":"10.1016\/j.jphs.2016.03.012_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0008-8749(90)90302-8","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus III potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha\/beta","volume":"126","author":"von Hoegen","year":"1990","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jphs.2016.03.012_bib32","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.170.4.1814","article-title":"TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus","volume":"170","author":"Washburn","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2016.03.012_bib33","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Schirrmacher","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jphs.2016.03.012_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-4615-5357-1_41","article-title":"Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy","volume":"451","author":"Schirrmacher","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jphs.2016.03.012_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","article-title":"Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy","volume":"159","author":"Bai","year":"2014","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jphs.2016.03.012_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2307\/1590355","article-title":"Atypical disease produced in chickens by Newcastle disease virus isolated from exotic birds","volume":"28","author":"Brugh","year":"1984","journal-title":"Avian Dis"},{"key":"10.1016\/j.jphs.2016.03.012_bib37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0042-6822(91)90420-G","article-title":"Identification of endoprotease activity in the trans Golgi membranes of rat liver cells that specifically processes in\u00a0vitro the fusion glycoprotein precursor of virulent Newcastle disease virus","volume":"184","author":"Sakaguchi","year":"1991","journal-title":"Virology"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T05:42:02Z","timestamp":1655617322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861316300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1347861316300068"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2016.03.012","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant Newcastle disease virus (NDV\/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2016.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}